Envoy Medical, Inc. Class A (COCH)

In August 2025, Envoy Medical secured patents in the United States, Australia, and Hong Kong. In September 2025, the company announced operational updates, including debt extinguishment and clinical trial expansion. In October 2025, the stock surged after FDA approval to expand the Acclaim® clinical trial, and Nasdaq granted continued listing until February 2026. In November 2025, the company reported a Q3 loss, missed revenue estimates, and announced a registered direct offering. In December 2025, Envoy Medical reached the midway point of enrollment in its pivotal clinical study for the Acclaim® cochlear implant, completed the first set of activations in the final stage of the trial, secured a new Australian patent, and filed for a share offering. In January 2026, Envoy Medical presented at the Small Cap Growth Virtual Investor Conference. In February 2026, the stock experienced a price decline.

There is no direct information available to indicate significant demand seasonality for Envoy Medical, Inc.'s products and services. Demand is likely driven by medical necessity and patient eligibility rather than seasonal fluctuations.

Envoy Medical, Inc. is a hearing health company focused on fully implanted hearing solutions. They operate in the Medical Devices industry, specifically in the Orthopedic, Prosthetic & Surgical Appliances & Supplies sector. Their core technologies include the Esteem® FI-AMEI, FDA-approved and commercially available for adults with moderate to severe sensorineural hearing loss, and the Acclaim® cochlear implant, an investigational device in a pivotal clinical trial for severe to profound sensorineural hearing loss, which received Breakthrough Device Designation from the FDA in 2019.

Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota, United States. The Esteem® product is commercially available in the U.S., and the company has patents in Australia and Europe, indicating potential for future international expansion. The company sees substantial market opportunities outside the United States, with approximately 50% of the hearing device market being international.

Envoy Medical's brand reputation has been positively influenced by advancements in its fully implanted hearing technology, including securing patents and FDA approval to expand the Acclaim® clinical trial, leading to a stock price increase. Successful completion of initial trial phases also bolstered confidence. However, Q3 2025 financial results, reporting a loss and missed revenue estimates, along with a recent stock price decline in February 2026, could negatively impact its financial reputation.

Institutional ownership of Envoy Medical, Inc. is 59.25%. Insider ownership is reported as 5.70% and 49.46% by different sources. Charles Brynelsen and Mona Chetan Patel have purchased COCH shares in the last 24 months, totaling 55,000 shares for $98,950.00.